# Agios Pharmaceuticals share price today (Agios Pharmaceuticals, Inc., AGIO)

> Agios Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AGIO · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/agio

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $28.27 (−30.5% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: −₹0.1 B (one-off item, see below)
- ROE: −35%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Agios Pharmaceuticals share price today? Agios Pharmaceuticals, Inc.'s share price was $28.27 at the close on 5 November 2026. It has been falling for 2 weeks. That is 11.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $24 and $44, and at that close it sat 20% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 10 years the share price moved −34% while the S&P 500 moved +245%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Agios Pharmaceuticals pay? Agios Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Agios Pharmaceuticals on? Agios Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Agios Pharmaceuticals profitable? Agios Pharmaceuticals, Inc. posted a net loss of ₹0.1 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.4 B. That loss is 225.1% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 B. 11 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was −₹0.4 B (−161.3% on the year before). Read this profit with care: at −₹0.1 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −247.1% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Agios Pharmaceuticals make, and is it growing? Agios Pharmaceuticals, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, +259.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 3 years it has grown 56.0% a year on average. The last full year, FY25, came in at ₹0.1 B. The last four reported quarters add to ₹0.1 B. FY25 revenue was ₹0.1 B, +48.0% on the year before. Recent pace: the last four quarters grew +131.7% on average, against 56.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +140.6%, against +77.2% a year over the last 8 quarters (accelerating). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Agios Pharmaceuticals keep? Agios Pharmaceuticals, Inc. has almost no sales yet: FY25 revenue was ₹0.1 B. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Agios Pharmaceuticals' profit turning into cash? Agios Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.4 B of cash, against −₹0.4 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.4 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Agios Pharmaceuticals' cash go? Agios Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Agios Pharmaceuticals' P/E ratio, and how does it compare with its own history? Agios Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Agios Pharmaceuticals business getting better or worse? Agios Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 11 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Agios Pharmaceuticals earn on its capital? Agios Pharmaceuticals, Inc. earned a ROE of −35% in FY25. That is up from a low of −43% in FY23. Its return on capital used (ROIC) is left out: on sales this small it reads −252%, a number that says nothing useful about the business. ## Does Agios Pharmaceuticals have too much debt? Agios Pharmaceuticals, Inc. has total debt of ₹0.0 B against shareholder equity of ₹1.0 B as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.08 in FY21 to 0.03 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Agios Pharmaceuticals shareholding pattern? 13.8% of Agios Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Agios Pharmaceuticals from balance-sheet trouble? For Agios Pharmaceuticals, Inc., the Z-score is 12.47. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 12.47 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Agios Pharmaceuticals rank in its industry? There is no score against its industry: Agios Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Agios Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Agios Pharmaceuticals in size? Agios Pharmaceuticals is the 84th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Maravai LifeSciences Holdings, Inc., Stoke Therapeutics, Inc. and Zenas BioPharma, Inc. Just below it: Nurix Therapeutics, Inc., Generate Biomedicines, Inc. and Novavax, Inc. ### Biotechnology companies close in size

1. [Maravai LifeSciences Holdings, Inc.](https://www.sectoralpha.in/us/stocks/mrvi) $1.8 billion
2. [Stoke Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/stok) $1.7 billion
3. [Zenas BioPharma, Inc.](https://www.sectoralpha.in/us/stocks/zbio) $1.7 billion
4. Agios Pharmaceuticals, Inc. $1.7 billion
5. [Nurix Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/nrix) $1.6 billion
6. [Generate Biomedicines, Inc.](https://www.sectoralpha.in/us/stocks/genb) $1.6 billion
7. [Novavax, Inc.](https://www.sectoralpha.in/us/stocks/nvax) $1.6 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Perdoceo Education Corporation](https://www.sectoralpha.in/us/stocks/prdo) $1.9 billion · Education & Training Services
2. [Genius Sports Limited](https://www.sectoralpha.in/us/stocks/geni) $1.9 billion · Internet Content & Information
3. Agios Pharmaceuticals, Inc. $1.9 billion
4. [ARMOUR Residential REIT, Inc.](https://www.sectoralpha.in/us/stocks/arr) $1.9 billion · REIT - Mortgage
5. [Adeia Inc.](https://www.sectoralpha.in/us/stocks/adea) $1.9 billion · Software - Application

## What else do people ask about Agios Pharmaceuticals? ### What were Agios Pharmaceuticals's latest quarterly results? Agios Pharmaceuticals, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.1 B for the Jun 2026 quarter. The operating margin was −247.1%, 773.0 percentage points higher than a year earlier (as of 5 November 2026). ### What is Agios Pharmaceuticals's market cap? Agios Pharmaceuticals, Inc.'s market capitalisation is $1.7 B at a stock price of $28.27. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Agios Pharmaceuticals performing? Agios Pharmaceuticals, Inc.'s share price has been falling for 2 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Agios Pharmaceuticals's stock price go up? This page does not forecast Agios Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $28.27, and it has been falling for 2 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### What could break the Agios Pharmaceuticals story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Agios Pharmaceuticals a stock worth studying right now? What the numbers show: Agios Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.